# AIFA places three new medicines in class pending reimbursement assessment > Italy’s medicines agency published 1 October determinations for Itvisma, Jascayd and Liraglutide Stada on 17 October. All three were placed in class C(nn), for medicines not yet assessed for reimbursement. - Canonical URL: https://newsverum.com/en/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026 - Publisher: Newsverum - Section: Health - Country: Italy - Published: 2026-10-18T23:00:19+00:00 - Updated: 2026-10-18T23:00:19+00:00 - Event / data period: 2026-10-18 - Other editions: [Türkçe](https://newsverum.com/tr/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md), [العربية](https://newsverum.com/ar/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md), [Français](https://newsverum.com/fr/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md), [Español](https://newsverum.com/es/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md), [Deutsch](https://newsverum.com/de/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md), [Português](https://newsverum.com/pt/news/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026.md) AIFA’s three determinations dated 1 October were published in Italy’s Official Gazette on 17 October. They classify Itvisma, based on onasemnogene abeparvovec; Jascayd, containing nerandomilast; and Liraglutide Stada, containing liraglutide, as newly authorised human medicines. The determinations took effect on 18 October. All three products were placed in class C(nn), which AIFA defines for medicines not yet assessed for reimbursement. This classification by itself is not a reimbursement decision or confirmation that sales have begun. A separate AIFA supply-regime document for its 7–11 September committee meeting lists hospital-only use for Itvisma and prescription-only supply for Liraglutide Stada. ## Data ### Three medicine classifications published by AIFA on 17 October The determinations were adopted on 1 October and place each product in class C(nn), before reimbursement assessment. Methodology: Classes and active substances are taken from AIFA’s determinations. C(nn) placement does not mean reimbursement assessment is complete. | Medicine | Active substance | Reimbursement assessment class | |---|---|---| | Itvisma | onasemnogene abeparvovec | C(nn) - not yet assessed for reimbursement | | Jascayd | nerandomilast | C(nn) - not yet assessed for reimbursement | | Liraglutide Stada | liraglutide | C(nn) - not yet assessed for reimbursement | Sources: · Download data: [JSON](https://newsverum.com/api/v1/articles/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026/data/aifa-new-medicine-classifications?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/italy-aifa-places-three-new-medicines-in-non-negotiated-class-2026/data/aifa-new-medicine-classifications?lang=en&format=csv) ## Sources - [Agenzia Italiana del Farmaco (AIFA)]() (Source checked: 2026-10-19; Published: 2026-10-17) --- Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)